CN112724168B - Chiral pyridine derived N, B ligand, preparation method and application in iridium-catalyzed asymmetric boronation reaction - Google Patents

Chiral pyridine derived N, B ligand, preparation method and application in iridium-catalyzed asymmetric boronation reaction Download PDF

Info

Publication number
CN112724168B
CN112724168B CN202011602455.2A CN202011602455A CN112724168B CN 112724168 B CN112724168 B CN 112724168B CN 202011602455 A CN202011602455 A CN 202011602455A CN 112724168 B CN112724168 B CN 112724168B
Authority
CN
China
Prior art keywords
chiral
formula
ligand
pyridine
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011602455.2A
Other languages
Chinese (zh)
Other versions
CN112724168A (en
Inventor
李鹏飞
宋沛东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xian Jiaotong University
Original Assignee
Xian Jiaotong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xian Jiaotong University filed Critical Xian Jiaotong University
Priority to CN202011602455.2A priority Critical patent/CN112724168B/en
Publication of CN112724168A publication Critical patent/CN112724168A/en
Application granted granted Critical
Publication of CN112724168B publication Critical patent/CN112724168B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/18Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
    • B01J31/1805Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
    • B01J31/181Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine
    • B01J31/184Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine mixed aromatic/aliphatic ring systems, e.g. indoline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00Asymmetric syntheses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/16Ring systems of three rings containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/113Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/0825Preparations of compounds not comprising Si-Si or Si-cyano linkages
    • C07F7/083Syntheses without formation of a Si-C bond
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82Metals of the platinum group
    • B01J2531/827Iridium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Chiral pyridine derived N, B ligand, preparation method and application in iridium-catalyzed asymmetric boronization reaction, namely chiral pyridine derivative and PhMe2Si‑B(NiPr2)2Reacting in toluene at 125-135 ℃ to obtain chiral pyridine derived N, B ligand; the ligand is used in iridium catalytic asymmetric boronization, as the ligand is an N and B bidentate ligand, the catalytic activity of central metal iridium can be obviously improved, the chiral pyridine part is a rigid fused ring structure framework, the whole ligand has a relatively rigid and stable chiral space, a complex is formed after coordination with the metal iridium and is stable, the chiral environment cannot be changed in the reaction process, and meanwhile, the steric hindrance of the ortho position of the pyridine cannot be obviously increased due to the introduction of a five-membered ring and a three-membered ring, so that the catalytic activity of the metal iridium is influenced. The ligand of the invention shows excellent reaction activity and enantioselectivity in the iridium-catalyzed asymmetric boronation reaction.

Description

Chiral pyridine derived N, B ligand, preparation method and application in iridium-catalyzed asymmetric boronation reaction
Technical Field
The invention belongs to the technical field of fine chemical engineering, and relates to a chiral pyridine derived N, B ligand, a preparation method and application thereof in iridium-catalyzed asymmetric boronization.
Background
The chiral ligand is a key part for regulating and controlling the activity and reaction stereoselectivity of the catalyst in asymmetric metal catalysis and realizing the synthesis of a single enantiomer of a product. Pyridine is a ligand structural unit which is most widely applied in catalysis, but a chiral pyridine skeleton which is lack of universality so far restricts the development of a plurality of asymmetric catalytic reactions. For example,
Figure BDA0002869186880000011
chiral Bipyridine Ligand PINDY is synthesized from natural monoterpene Pinene and applied to the reactions of cyclopropanation, Allylic Oxidation and the like (PINDY: A Novel, pine-depleted dipyridine Ligand and Its Application in asymmetry Copper (I) -Catalyzed Allyllic Oxidation, Malkov, A.V.; Bella, M.J.; Langer, V.;
Figure BDA0002869186880000012
leg.2000, 2,3047. (p.org). Because of the difficulty of structural modification of PINDY, the structure cannot be further optimized, and the reactions are only moderate to goodEnantioselectivity. The Fu topic group skillfully designs Planar Chiral pyridine ligand BPY containing ferrocene skeleton, and obtains higher selectivity in copper-catalyzed cyclopropanation reaction using bulky steric diazoacetate (Applications of Planar-Chiral Heterocycles as Ligands in asymmetry Catalysis, Fu, G.C. Acc.chem.Res.2006,39,853.). The introduction of chiral elements on a planar structure is difficult, the contradiction between activity and selectivity caused by steric hindrance is difficult, the structure has poor modifiability, and the modular synthesis is difficult, which is a main challenge facing the design of chiral pyridine.
Disclosure of Invention
Aiming at the problems existing in the design and synthesis aspects of the prior chiral pyridine, the invention aims to provide a chiral pyridine derived N, B ligand, a preparation method and application in iridium-catalyzed asymmetric boronation reaction.
The invention is realized by the following technical scheme:
the structural general formula of the chiral pyridine derived N, B ligand is shown as formula (1):
Figure BDA0002869186880000021
r is methyl, ethyl, isopropyl, benzyl, 3, 5-dimethylbenzyl, 3, 5-diisopropylbenzyl, 3, 5-di-tert-butylbenzyl, 3, 5-diphenylbenzyl, phenyl, 3, 5-dimethylphenyl, 3, 5-dimethoxyphenyl, 3, 5-diisopropylphenyl, 3, 5-di-tert-butylphenyl or 3, 5-diphenylphenyl.
A process for preparing chiral pyridine-derived N, B ligand by reacting chiral pyridine derivative shown in formula (9) with PhMe2Si-B(NiPr2)2Reacting in toluene at 125-135 ℃ to obtain chiral pyridine-derived N, B ligand shown in formula (1);
Figure BDA0002869186880000022
wherein R is methyl, ethyl, isopropyl, benzyl, 3, 5-dimethylbenzyl, 3, 5-diisopropylbenzyl, 3, 5-di-tert-butylbenzyl, 3, 5-diphenylbenzyl, phenyl, 3, 5-dimethylphenyl, 3, 5-dimethoxyphenyl, 3, 5-diisopropylphenyl, 3, 5-di-tert-butylphenyl or 3, 5-diphenylphenyl.
The invention has the further improvement that the concrete process is as follows: under nitrogen atmosphere, 1mmol of chiral pyridine derivative shown as formula (9) and 1.1-1.3 mmol of PhMe2Si-B(NiPr2)2And mixing the chiral pyridine and anhydrous toluene, and then reacting for 24-36 h at 125-135 ℃ to obtain the chiral pyridine derived N, B ligand.
In a further improvement of the present invention, the chiral pyridine derivative represented by formula (9) is prepared by the following process:
mixing chiral diol, ketal, p-toluenesulfonic acid, stannous chloride and dichloroethane shown in formula (7), and reacting under reflux to obtain chiral chloropyridine derivative shown in formula (8);
Figure BDA0002869186880000031
the ketal formula is as follows:
Figure BDA0002869186880000032
wherein R is methyl, ethyl, isopropyl, benzyl, 3, 5-dimethylbenzyl, 3, 5-diisopropylbenzyl, 3, 5-di-tert-butylbenzyl, 3, 5-diphenylbenzyl, phenyl, 3, 5-dimethylphenyl, 3, 5-dimethoxyphenyl, 3, 5-diisopropylphenyl, 3, 5-di-tert-butylphenyl or 3, 5-diphenylphenyl;
mixing a chiral chloropyridine derivative shown in a formula (8) and phenylenediamine in palladium acetate, 2 '-bis- (diphenylphosphino) -1,1' -binaphthyl and toluene, and then carrying out C-N bond coupling reaction to obtain a chiral pyridine derivative shown in a formula (9);
Figure BDA0002869186880000033
the further improvement of the invention is that chiral diol, ketal, p-toluenesulfonic acid, stannous chloride, 4A molecular sieve and anhydrous dichloroethane are mixed and stirred for 6-8 h at 80-100 ℃ to obtain the chiral chloropyridine derivative shown in formula (8); wherein the ratio of the amounts of the chiral diol, the ketal, the p-toluenesulfonic acid and the stannous chloride is 1: (1.5-2): (0.02-0.05): (0.02-0.05);
mixing the chiral chloropyridine derivative shown in the formula (8), o-phenylenediamine, palladium acetate, 2,2 '-bis- (diphenylphosphino) -1,1' -binaphthyl, cesium carbonate and anhydrous toluene under a nitrogen atmosphere, and stirring at 90-100 ℃ for 10-16 h to obtain the chiral pyridine derivative shown in the formula (9); wherein the ratio of the amounts of the chiral chloropyridine derivative, o-phenylenediamine, palladium acetate, 2 '-bis- (diphenylphosphino) -1,1' -binaphthyl and cesium carbonate is 1: (1.2-2): (0.02-0.05): (0.04-0.1): (1.5-2).
In a further development of the invention, the chiral diol is prepared by the following process:
(1) performing cyclopropanation reaction on bromo-cyclopentenone and malonic diester to generate ketone shown in a formula (2);
Figure BDA0002869186880000041
wherein R is1Is methyl, ethyl, isopropyl, tert-butyl or benzyl;
(2) reacting ketone shown in a formula (2) with (R) -tert-butyl sulfinamide and tetraethyl titanate to obtain sulfinyl imine, and hydrolyzing to obtain chiral ketone shown in a formula (3) or a formula (3');
Figure BDA0002869186880000042
(3) placing chiral ketone shown in a formula (3) or a formula (3') and hydroxylamine into ethanol for reaction to obtain oxime shown in a formula (4);
Figure BDA0002869186880000043
(4) adding oxime shown in a formula (4) into toluene, adding iron powder, acetic anhydride and acetic acid, and reacting to obtain enamide shown in a formula (5);
Figure BDA0002869186880000044
(5) dissolving the enamine shown in the formula (5) in N, N-dimethylformamide, then dropwise adding phosphorus oxychloride, and reacting to obtain the chiral chloropyridine derivative shown in the formula (6);
Figure BDA0002869186880000045
(6) the chiral chloropyridine derivative shown in the formula (6) is dissolved in dichloromethane, and an ester group is reduced to a hydroxyl group by diisobutylaluminum hydride to obtain a chiral diol.
The invention has the further improvement that the specific process of the step (1) is as follows: mixing bromo-cyclopentenone, diethyl malonate, tetrahexylammonium bromide, potassium carbonate and 1, 2-dichloroethane, and stirring at 80-90 ℃ for 8-12 hours to obtain racemic ketone shown in formula (2); wherein the mass ratio of the brominated cyclopentenone, diethyl malonate, tetrahexylammonium bromide and potassium carbonate is 1: (1.0-1.5): (0.1-0.2): (4-6);
the specific process of the step (2) is as follows: mixing racemic ketone (R) -tert-butyl sulfenamide shown in formula (2), tetraethoxytitanate and anhydrous 1, 2-dichloroethane, and stirring at 80-90 ℃ for 12-18 h to obtain a pair of enantiomeric ketone shown in formula (3) and formula (3'); wherein the ratio of the amounts of racemic ketone, tetraethyl (R) -tert-butylsulfinamide UI titanate is 1: (1.0-1.5): (2-3);
the specific process of the step (3) is as follows: dissolving chiral ketone and hydroxylamine aqueous solution shown in formula (3) or formula (3') in ethanol, and stirring for 2-4 h at 60-80 ℃; obtaining oxime represented by a formula (4); wherein the ratio of the amount of substance of chiral ketone to hydroxylamine is 1: (3-5).
The invention has the further improvement that the specific process of the step (4) is as follows: dissolving oxime shown in a formula (4) in toluene, then adding reduced iron powder, dropwise adding a mixture of acetic acid and acetic anhydride at 0 ℃, and stirring for 2-4 h to obtain enamide shown in a formula (5); wherein the mass ratio of the oxime, the reduced iron powder, the acetic acid and the acetic anhydride is 1: (8-10): (3-5): (3-5);
the specific process of the step (5) is as follows: dissolving enamine shown in a formula (5) in anhydrous N, N-dimethylformamide, dropwise adding phosphorus oxychloride at 0 ℃, heating to 60-80 ℃ after dropwise adding, and reacting for 6-10 h to obtain chiral chloropyridine derivatives shown in a formula (6); wherein the mass ratio of the enamine to the phosphorus oxychloride is 1: (7-10);
the specific process of the step (6) is as follows: dissolving the chiral chloropyridine derivative shown in the formula (6) in anhydrous dichloromethane, dropwise adding n-hexane solution of diisobutyl aluminum hydride at 0 ℃, and stirring at room temperature for 4-6 hours after dropwise adding to obtain chiral diol shown in the formula (7); wherein the ratio of the amount of the chiral chloropyridine derivative to the amount of the diisobutylaluminum hydride is 1 mmol: 6-8 mL.
The application of the chiral pyridine-derived N, B ligand in iridium-catalyzed asymmetric boronation reaction is provided.
The further improvement of the invention is that in an argon glove box, the chiral N, B ligand, methoxy (cyclooctadiene) iridium dimer and bis pinacol boric acid ester are pre-stirred in N-hexane for 5-30 min, diaryl pyridine is added, stirring is carried out at 60-80 ℃ for 2-8 h, and purification is carried out to obtain a chiral aryl boron compound; wherein the ratio of the amounts of the chiral N, B ligand, methoxy (cyclooctadiene) iridium dimer and bis (pinacolato) borate is (0.04-0.1): (0.02-0.05): (1.2-2): 1.
compared with the prior art, the invention has the following beneficial effects:
the ligand is used in iridium catalytic asymmetric boronization, as the ligand is an N and B bidentate ligand, the catalytic activity of central metal iridium can be obviously improved, the chiral pyridine part is a rigid fused ring structure framework, the whole ligand has a relatively rigid and stable chiral space, a complex is formed after coordination with the metal iridium and is stable, the chiral environment cannot be changed in the reaction process, and meanwhile, the steric hindrance of the ortho position of the pyridine cannot be obviously increased due to the introduction of a five-membered ring and a three-membered ring, so that the catalytic activity of the metal iridium is influenced. In addition, the chiral ligand has a hydroxyl functional group with adjustable structure height, can conveniently derive a series of chiral N and B ligands, and can improve the enantioselectivity of chiral aryl boronization products while obtaining high yield. The ligand of the invention has excellent reaction activity and enantioselectivity in the iridium-catalyzed asymmetric boronization reaction, and the obtained chiral aryl boron product has good enantioselectivity and high yield. The raw materials for synthesizing the ligand have low cost, are simple and easy to obtain, and are convenient to synthesize.
The chiral ligand of the invention shows excellent reaction activity and enantioselectivity in the asymmetric boronization reaction catalyzed by iridium. Therefore, the invention provides a new framework chiral ligand for the development of asymmetric catalysis, and provides a new method for preparing the chiral aryl boron compound.
Furthermore, the chiral chloropyridine compound with rigid fused ring structure skeleton and adjustable structure height is designed and synthesized, and is further derived into chiral N and B ligands.
Drawings
FIG. 1 shows chiral pyridine-derived N, B ligands of formula (1) in an embodiment of the present invention1H NMR spectrum, wherein the R group is benzyl.
Detailed Description
The present invention will now be described in further detail with reference to specific examples, which are intended to be illustrative, but not limiting, of the invention.
A chiral chloropyridine compound with a rigid fused ring structure skeleton and a height-adjustable structure is further derivatized into a chiral N, B ligand, and the chiral ligand shows excellent reaction activity and enantioselectivity in an iridium-catalyzed asymmetric boronization reaction.
The structural general formula of the chiral pyridine derived N, B ligand provided by the invention is shown as formula (1):
Figure BDA0002869186880000071
a process for preparing chiral pyridine-derived N, B ligands comprising the steps of:
the first step is as follows: mixing bromo-cyclopentenone (1mmol), malonic diester (1.0-1.5 mmol), tetrahexylammonium bromide (0.1-0.2 mmol), potassium carbonate (4-6 mmol) and 1, 2-dichloroethane (the concentration of bromo-cyclopentenone is 0.5-1 mol/L), and stirring at 80-90 ℃ for 8-12 hours. And (3) post-reaction treatment: filtering, collecting filtrate, concentrating, and purifying by column chromatography to obtain racemic ketone represented by formula (2).
Figure BDA0002869186880000072
Wherein R is1Methyl, ethyl, isopropyl, tert-butyl, benzyl or the like.
The second step is that: mixing 1mmol of racemic ketone (shown in formula (2), (1.0-1.5 mmol of R) -tert-butyl sulfenamide, 2-3 mmol of tetraethyl titanate and anhydrous 1, 2-dichloroethane (the concentration of the racemic ketone is 0.5-1 mol/L), and stirring at 80-90 ℃ for 12-18 h. And (3) post-reaction treatment: quenching reaction with saturated ammonium chloride solution at 0 deg.C, vacuum filtering, collecting filtrate, extracting with dichloromethane, drying organic phase, concentrating, and purifying by column chromatography to obtain diastereoisomer sulfinylimine. And then, respectively carrying out hydrochloric acid (2mol/L) hydrolysis on the pair of diastereoisomer sulfinylimines obtained by purification, and using methanol (the concentration of the pair of diastereoisomer sulfinylimines obtained by purification is 0.2-0.4 mol/L) as a solvent. After the reaction is finished, ethyl acetate is used for extraction, an organic phase is dried, concentrated, and separated and purified by column chromatography to obtain a pair of enantiomer ketones shown in formula (3) and formula (3').
Figure BDA0002869186880000081
The third step: dissolving 1mmol of chiral ketone (shown in formula (3)) and 3-5 mmol of hydroxylamine (50% aqueous solution) in ethanol (the concentration of the chiral ketone is 0.5-1 mol/L), and stirring at 60-80 ℃ for 2-4 h. After the reaction, extraction was performed with ethyl acetate, and the organic phase was dried and concentrated to obtain an oxime represented by the formula (4).
Figure BDA0002869186880000082
The fourth step: dissolving oxime (1mmol) shown in formula (4) in toluene (the concentration of the oxime is 0.5-1 mol/L), adding reduced iron powder (8-10 mmol), dropwise adding a mixture of acetic acid (3-5 mmol) and acetic anhydride (3-5 mmol) at 0 ℃, and vigorously stirring at room temperature for 2-4 h. And (3) after the reaction is finished, performing suction filtration, washing a filter cake with ethyl acetate, collecting filtrate, adjusting the pH value to 6-7 with a saturated sodium carbonate solution, extracting with ethyl acetate, drying an organic phase, concentrating, and performing column chromatography separation and purification to obtain the enamide shown in the formula (5).
Figure BDA0002869186880000083
The fifth step: dissolving 1mmol of enamide shown in a formula (5) in anhydrous N, N-dimethylformamide (3-5 mmol), dropwise adding 7-10 mmol of phosphorus oxychloride at 0 ℃, heating the system to 60-80 ℃ after dropwise adding, and reacting for 6-10 h. After the reaction is finished, diluting the reaction solution with a proper amount of ethyl acetate at low temperature, slowly pouring the diluted reaction solution into a proper amount of saturated sodium bicarbonate solution, adjusting the pH value to 7-8, extracting with ethyl acetate, drying an organic phase, concentrating, and carrying out column chromatography separation and purification to obtain the chiral chloropyridine derivative shown in the formula (6).
Figure BDA0002869186880000091
And a sixth step: dissolving 1mmol of chiral chloropyridine derivative shown in formula (6) in anhydrous dichloromethane (the concentration of the chiral chloropyridine derivative is 0.5-1 mol/L), dropwise adding 1mol/L diisobutylaluminum hydride normal hexane solution (6-8 mL of diisobutylaluminum hydride) at 0 ℃, and stirring at room temperature for 4-6 h after dropwise adding. After the reaction is finished, slowly quenching the reaction by using a saturated ammonium chloride solution at a low temperature, adding a proper amount of methanol, stirring for 30 minutes, extracting by using dichloromethane, drying an organic phase, concentrating, and carrying out column chromatography separation and purification to obtain the chiral diol shown in the formula (7).
Figure BDA0002869186880000092
The seventh step: mixing chiral diol (1mmol) shown in formula (7), ketal (1.5-2 mmol), p-toluenesulfonic acid (0.02-0.05 mmol), stannous chloride (0.02-0.05 mmol) and a proper amount of 4A molecular sieve with anhydrous dichloroethane (the concentration of the chiral diol is 0.5-1 mol/L), and stirring at 80-100 ℃ for 4-8 h. And (3) post-treatment: and (3) carrying out suction filtration, collecting the filtrate, concentrating, and carrying out column chromatography separation and purification to obtain the chiral chloropyridine derivative shown in the formula (8).
Figure BDA0002869186880000093
Wherein R is methyl, ethyl, isopropyl, benzyl (including benzyl with substituent on benzene ring: 3, 5-dimethylbenzyl, 3, 5-diisopropylbenzyl, 3, 5-di-tert-butylbenzyl, 3, 5-diphenylbenzyl) or phenyl (including phenyl with substituent on benzene ring: 3, 5-dimethylphenyl, 3, 5-dimethoxyphenyl, 3, 5-diisopropylphenyl, 3, 5-di-tert-butylphenyl or 3, 5-diphenylphenyl), etc.
Eighth step: mixing 1mmol of chiral chloropyridine derivative represented by formula (8), 1.2 to 2mmol of o-phenylenediamine, 0.02 to 0.05mmol of palladium acetate, 0.04 to 0.1mmol of 2,2 '-bis- (diphenylphosphino) -1,1' -binaphthyl, 1.5 to 2mmol of cesium carbonate and anhydrous toluene (the concentration of the chiral chloropyridine derivative is 0.3 to 0.5mol/L) in a nitrogen atmosphere, and stirring at 90 to 100 ℃ for 10 to 16 hours.
And (3) post-treatment: and (3) carrying out suction filtration, collecting the filtrate, concentrating, and carrying out column chromatography separation and purification to obtain the chiral pyridine derivative shown in the formula (9).
Figure BDA0002869186880000101
The ninth step: under nitrogen atmosphere, chiral pyridine derivative (1mmol) shown in formula (9) and silicon boron reagentPhMe2Si-B(NiPr2)2(1.1-1.3 mmol) and anhydrous toluene (the concentration of the chiral pyridine derivative is 0.5-1 mol/L), and reacting for 24-36 h at 125-135 ℃. And (3) post-treatment: and (3) pumping the toluene under anhydrous and anaerobic conditions, and washing the obtained yellow solid for 3-5 times by using anhydrous N-hexane to obtain a white or light yellow product, namely the target N, B ligand shown in the formula (1).
Figure BDA0002869186880000102
Wherein R is methyl, ethyl, isopropyl, benzyl, 3, 5-dimethylbenzyl, 3, 5-diisopropylbenzyl, 3, 5-di-tert-butylbenzyl, 3, 5-diphenylbenzyl, phenyl, 3, 5-dimethylphenyl, 3, 5-dimethoxyphenyl, 3, 5-diisopropylphenyl, 3, 5-di-tert-butylphenyl or 3, 5-diphenylphenyl, etc.
The application of the chiral pyridine derived N, B ligand in iridium-catalyzed asymmetric boronization comprises the following steps:
in an argon glove box, pre-stirring chiral N, B ligand (0.04-0.1 mmol), methoxy (cyclooctadiene) iridium dimer (0.02-0.05 mmol) and bis (pinacolato) borate (1.2-2 mmol) in N-hexane (0.1-0.2 mol/L) for 5-30 min, adding substrate diaryl pyridine (1mmol), stirring at 60-80 ℃ for 2-8 h, and separating and purifying the obtained crude product by column chromatography to obtain the corresponding chiral aryl boron compound.
The structure of the chiral aryl boron compound is shown as the formula (10):
Figure BDA0002869186880000111
wherein R is1,R2Represents different functional group substituents connected with the ortho, meta and para positions of the aromatic ring.
The following are specific examples.
Example 1
Synthesis of chiral pyridine-derived N, B ligands:
1.1)
Figure BDA0002869186880000112
in a 250mL single-necked flask, bromocyclopentenone (17.71g,110mmol), diethyl malonate (25.05mL,165mmol), tetrahexylammonium bromide (4.78g,11mmol), potassium carbonate (91.21g,660mmol), and 60mL 1, 2-dichloroethane were added, and heated at 90 ℃ under reflux for 8 hours. And (3) post-treatment: the reaction solution was filtered through a buchner funnel, and the filter cake was washed with dichloromethane, collected, concentrated, and subjected to column chromatography to separate and purify the racemic ketone represented by formula (2) (colorless oily liquid, 86% yield).
1.2)
Figure BDA0002869186880000113
Racemic ketone (9.6g,40mmol) represented by the formula (2), (R) -t-butylsulfinamide (5.33g,44mmol), tetraethyltitanate (18.25g,80mmol), 40mL of anhydrous 1, 2-dichloroethane were mixed, and heated at 90 ℃ under reflux for 12 hours. And (3) post-reaction treatment: quenching reaction with saturated ammonium chloride solution at 0 deg.C, vacuum filtering, collecting filtrate, extracting water phase with dichloromethane for 3 times, mixing organic phases, back-extracting with saturated saline solution, drying organic phase with anhydrous sodium sulfate, concentrating, and purifying by column chromatography to obtain a pair of diastereoisomer sulfinylimines (1: 1, each with 40% yield). The pair of diastereoisomeric sulfinamides obtained after purification is subsequently subjected to a respective hydrochloric acid hydrolysis, here for example a three-membered ring-up sulfinamide, which is dissolved in 30mL of methanol at 0 ℃ and stirred at room temperature for 6h with the addition of 2mol/L hydrochloric acid solution (20 mL). And (3) post-treatment: quenching the reaction with saturated ammonium carbonate solution at 0 deg.C, extracting the water phase with ethyl acetate for 3 times, mixing the organic phases, back-extracting with saturated saline, drying the organic phase with anhydrous sodium sulfate, concentrating, and purifying by column chromatography to obtain chiral ketone (colorless oily liquid, 95% yield) represented by formula (3).
1.3)
Figure BDA0002869186880000121
The chiral ketone (3.65g,15.2mmol) and hydroxylamine (3.01g,45.6mmol) (50% aqueous solution) obtained in the previous step were dissolved in 30mL of ethanol and heated under reflux for 4 hours. And (3) post-treatment: to the reaction solution was added saturated brine, the aqueous phase was extracted 3 times with ethyl acetate, the organic phases were combined, the organic phase was dried over anhydrous sodium sulfate, and concentrated to give the oxime represented by formula (4) (pale yellow solid, 100% yield).
1.4)
Figure BDA0002869186880000122
The oxime obtained in the previous step was dissolved in 15mL of toluene, and reduced iron powder (8.51g,152mmol) was added, and a mixture of acetic acid (2.74g,45.6mmol) and acetic anhydride (4.66g,45.6mmol) was added dropwise at 0 ℃ and stirred vigorously at room temperature for 4 hours. And (3) post-treatment: and (2) carrying out suction filtration, washing a filter cake with ethyl acetate, collecting filtrate, adjusting the pH value to 6-7 with a saturated sodium carbonate solution, extracting the water phase with ethyl acetate for 3 times, combining organic phases, carrying out back extraction with saturated saline solution, drying the organic phase with anhydrous sodium sulfate, concentrating, and carrying out column chromatography separation and purification to obtain the enamide (light yellow solid, 80% yield) shown in the formula (5).
1.5)
Figure BDA0002869186880000131
Into a 25mL dry Schlenk tube, enamide (3.40g,12.0mmol) obtained in the previous step was added, the system was purged with nitrogen 3 times, a mixture of N, N-dimethylformamide (2.77mL) and phosphorus oxychloride (7.81mL,84.0mmol) was added dropwise at 0 ℃ and, after completion of the addition, the system was heated to 80 ℃ for 6 hours. And (3) post-treatment: diluting the reaction solution with 20mL of ethyl acetate at 0 ℃, slowly pouring the diluted solution into a proper amount of saturated sodium bicarbonate solution, adjusting the pH to 7-8, extracting the aqueous phase with ethyl acetate for 3 times, combining the organic phases, carrying out back extraction with saturated saline, drying the organic phase with anhydrous sodium sulfate, concentrating, and carrying out column chromatography separation and purification to obtain the chiral chloropyridine derivative (white solid, 86% yield) shown in the formula (6).
1.6)
Figure BDA0002869186880000132
Chiral chloropyridine (2.8g,9mmol) obtained in the previous step and 18mL of anhydrous dichloromethane were added to a 100mL dry mouth piece under anhydrous and oxygen-free conditions, diisobutylaluminum hydride (54mL of a 1M n-hexane solution) was added dropwise at 0 ℃ from a constant pressure dropping funnel, and after completion of the addition, the mixture was stirred at room temperature for 6 hours. And (3) post-treatment: slowly quenching the reaction with a saturated ammonium chloride solution at 0 ℃, adding 30mL of methanol, stirring for 30 minutes, extracting the aqueous phase with dichloromethane for 5-6 times, combining the organic phases, drying with anhydrous sodium sulfate, concentrating, and carrying out column chromatography separation and purification to obtain the chiral diol (white solid, 90% yield) shown in the formula (7).
1.7)
Figure BDA0002869186880000141
In a dry Schlenk tube, the chiral diol (34mg,0.15mmol) obtained in the previous step, 2, 2-dimethoxypropane (31.2mg,0.3mmol), p-toluenesulfonic acid monohydrate (1.5mg,0.0075mmol), stannous chloride (1.5mg,0.0075mmol), an appropriate amount of 4A molecular sieve, and 1mL of anhydrous 1, 2-dichloroethane were added and reacted at 100 ℃ for 4 hours. And (3) post-treatment: the reaction solution was filtered with a buchner funnel, and the filter cake was washed with dichloromethane, and the filtrate was collected, concentrated, and subjected to column chromatography separation and purification to obtain a chiral chloropyridine derivative represented by formula (8) (white solid, 93% yield).
1.8)
Figure BDA0002869186880000142
To a dry Schlenk tube, the chiral chloropyridine derivative (34.5mg,0.13mmol) obtained in the previous step, o-phenylenediamine (17.3mg,0.16mmol), palladium acetate (1.5mg,0.0065mmol), 2,2 '-bis- (diphenylphosphino) -1,1' -binaphthyl (4mg,0.0065mmol), cesium carbonate (85mg,0.26mmol) were added, the reaction tube was purged with nitrogen three times, 1mL of anhydrous toluene was added under a nitrogen stream, and the reaction was carried out at 100 ℃ for 12 hours. And (3) post-treatment: the reaction solution was filtered through a suction filter funnel, and the filter cake was washed with dichloromethane, and the filtrate was collected, concentrated, and purified by column chromatography to obtain a chiral pyridine derivative represented by formula (9) (white solid, 88% yield).
1.9)
Figure BDA0002869186880000143
In a dry Schlenk tube, the chiral pyridine derivative (33.7mg,0.1mmol) obtained in the previous step, the reagent Si-B PhMe, were added2Si-B(NiPr2)2(45mg,0.13mmol), the nitrogen gas was purged into the reaction tube three times, and 1mL of anhydrous toluene was added under nitrogen flow to conduct reaction at 135 ℃ for 36 hours. And (3) post-treatment: and (3) pumping the toluene under anhydrous and anaerobic conditions, and washing the obtained yellow solid with anhydrous N-hexane for 3 times (1 mL each time) to obtain a white solid, namely the chiral N, B ligand L shown in the formula (1).
Example 1 preparation of the chiral N, B ligand1The H NMR spectrum is shown in FIG. 1.1H NMR(400MHz,CDCl3)δ7.21-7.11(m,2H),7.09-7.05(m,1H),6.81(dd,J=8.0,1.2Hz,1H),6.78-6.74(m,1H),6.13(d,J=8.3Hz,1H),6.02(s,1H),4.02(d,J=11.8Hz,1H),3.87(s,2H),3.68(d,J=12.4Hz,1H),3.36(dd,J=11.8,1.1Hz,1H),3.27-3.23(m,1H),3.06(dd,J=17.3,7.1Hz,1H),2.85(d,J=17.3Hz,1H),2.33(dd,J=6.3,1.6Hz,1H),1.97(t,J=6.7Hz,1H),1.46(s,3H),1.44(s,3H).
Example 2
1.1) in a 10mL single-necked flask, bromocyclopentenone (1mmol), diethyl malonate (1.0mmol), tetrahexylammonium bromide (0.15mmol), potassium carbonate (4mmol), and 2mL of 1, 2-dichloroethane were added, and heated at 84 ℃ under reflux for 10 hours. And (3) post-treatment: the reaction solution was filtered through a buchner funnel, and the filter cake was washed with dichloromethane, collected, concentrated, and subjected to column chromatography to separate and purify the racemic ketone represented by formula (2) (colorless oily liquid, 86% yield).
1.2) racemic ketone (1mmol), (R) -t-butylsulfinamide (1.2mmol) represented by formula (2), tetraethyltitanate (3mmol), 2mL anhydrous 1, 2-dichloroethane were mixed, and heated under reflux at 80 ℃ for 18 hours. And (3) post-reaction treatment: quenching reaction with saturated ammonium chloride solution at 0 deg.C, vacuum filtering, collecting filtrate, extracting water phase with dichloromethane for 3 times, mixing organic phases, back-extracting with saturated saline solution, drying organic phase with anhydrous sodium sulfate, concentrating, and purifying by column chromatography to obtain a pair of diastereoisomer sulfinylimines (1: 1, each with 40% yield). The pair of diastereoisomeric sulfinamides obtained after purification is subsequently subjected to a respective hydrochloric acid hydrolysis, here for example a three-membered ring-up sulfinamide, which is dissolved in 5mL of methanol at 0 ℃ and stirred at room temperature for 6 hours with the addition of 2mol/L hydrochloric acid solution (2 mL). And (3) post-treatment: quenching the reaction with saturated ammonium carbonate solution at 0 deg.C, extracting the water phase with ethyl acetate for 3 times, mixing the organic phases, back-extracting with saturated saline, drying the organic phase with anhydrous sodium sulfate, concentrating, and purifying by column chromatography to obtain chiral ketone (colorless oily liquid, 95% yield) represented by formula (3).
1.3) the chiral ketone (1mmol) obtained in the previous step, a 50% strength by mass aqueous solution of hydroxylamine (the amount of hydroxylamine substance is 4mmol) was dissolved in 2mL of ethanol and heated under reflux at 70 ℃ for 3 hours. And (3) post-treatment: to the reaction solution was added saturated brine, the aqueous phase was extracted 3 times with ethyl acetate, the organic phases were combined, the organic phase was dried over anhydrous sodium sulfate, and concentrated to give the oxime represented by formula (4) (pale yellow solid, 100% yield).
1.4) the oxime (1mmol) obtained in the previous step was dissolved in toluene, reduced iron powder (8mmol) was added, a mixture of acetic acid (3mmol) and acetic anhydride (3mmol) was added dropwise at 0 ℃ and stirred vigorously at room temperature for 2 hours. And (3) post-treatment: and (2) carrying out suction filtration, washing a filter cake with ethyl acetate, collecting filtrate, adjusting the pH value to 6-7 with a saturated sodium carbonate solution, extracting the water phase with ethyl acetate for 3 times, combining organic phases, carrying out back extraction with saturated saline solution, drying the organic phase with anhydrous sodium sulfate, concentrating, and carrying out column chromatography separation and purification to obtain the enamide (light yellow solid, 80% yield) shown in the formula (5).
1.5) in a 25mL dry Schlenk tube, adding the enamide (1mmol) obtained in the previous step, replacing nitrogen for 3 times, dropwise adding a mixture of N, N-dimethylformamide (4mL) and phosphorus oxychloride (10mmol) at 0 ℃, heating the system to 75 ℃ after dropwise adding, and reacting for 7 hours. And (3) post-treatment: diluting the reaction solution with 20mL of ethyl acetate at 0 ℃, slowly pouring the diluted solution into a proper amount of saturated sodium bicarbonate solution, adjusting the pH to 7-8, extracting the aqueous phase with ethyl acetate for 3 times, combining the organic phases, carrying out back extraction with saturated saline, drying the organic phase with anhydrous sodium sulfate, concentrating, and carrying out column chromatography separation and purification to obtain the chiral chloropyridine derivative (white solid, 86% yield) shown in the formula (6).
1.6) adding the chiral chloropyridine (1mmol) obtained in the previous step and anhydrous dichloromethane (2mL) into a 25mL dry branch mouth tube under anhydrous and oxygen-free conditions, dropwise adding a 1mol/L diisobutylaluminum hydride n-hexane solution (6 mL diisobutylaluminum hydride) at 0 ℃ by using a constant pressure dropping funnel, and after the dropwise addition is finished, stirring at room temperature for 4 hours. And (3) post-treatment: slowly quenching the reaction with a saturated ammonium chloride solution at 0 ℃, adding 10mL of methanol, stirring for 30 minutes, extracting the aqueous phase with dichloromethane for 5-6 times, combining the organic phases, drying with anhydrous sodium sulfate, concentrating, and carrying out column chromatography separation and purification to obtain the chiral diol (white solid, 90% yield) shown in the formula (7).
1.7) in a dry Schlenk tube, the chiral diol (1mmol) obtained in the previous step, 2, 2-dimethoxypropane (1.7mmol), p-toluenesulfonic acid monohydrate (0.03mmol), stannous chloride (0.05mmol), an appropriate amount of 4A molecular sieve and 1mL of anhydrous 1, 2-dichloroethane are added and reacted for 8 hours at 80 ℃. And (3) post-treatment: the reaction solution was filtered with a buchner funnel, and the filter cake was washed with dichloromethane, and the filtrate was collected, concentrated, and subjected to column chromatography separation and purification to obtain a chiral chloropyridine derivative represented by formula (8) (white solid, 93% yield).
1.8) in a dry Schlenk tube, the chiral chloropyridine derivative (1mmol) obtained in the previous step, o-phenylenediamine (1.2mmol), palladium acetate (0.02mmol), 2,2 '-bis- (diphenylphosphino) -1,1' -binaphthyl (0.04mmol), and cesium carbonate (1.5mmol) were added, the nitrogen gas was replaced three times in the reaction tube, and anhydrous toluene was added under a nitrogen stream to react at 100 ℃ for 10 hours. And (3) post-treatment: the reaction solution was filtered through a suction filter funnel, and the filter cake was washed with dichloromethane, and the filtrate was collected, concentrated, and purified by column chromatography to obtain a chiral pyridine derivative represented by formula (9) (white solid, 88% yield).
1.9) inAdding the chiral pyridine derivative (1mmol) obtained in the previous step and a silicon boron reagent PhMe into a dried Schlenk tube2Si-B(NiPr2)2(1.1mmol), the nitrogen gas was purged three times through the reaction tube, and anhydrous toluene was added under nitrogen flow to conduct a reaction at 130 ℃ for 30 hours. And (3) post-treatment: and (3) pumping the toluene under anhydrous and anaerobic conditions, and washing the obtained yellow solid with anhydrous N-hexane for 3 times (1 mL each time) to obtain a white solid, namely the chiral N, B ligand L shown in the formula (1).
Example 3
1.1) in a 10mL single-necked flask, bromocyclopentenone (1mmol), diethyl malonate (1.5mmol), tetrahexylammonium bromide (0.2mmol), potassium carbonate (5mmol), and 2mL of 1, 2-dichloroethane were added, and heated at 80 ℃ under reflux for 12 hours. And (3) post-treatment: the reaction solution was filtered through a buchner funnel, and the filter cake was washed with dichloromethane, collected, concentrated, and subjected to column chromatography to separate and purify the racemic ketone represented by formula (2) (colorless oily liquid, 86% yield).
1.2) racemic ketone (1mmol), (R) -t-butylsulfinamide (1.5mmol) represented by formula (2), tetraethyl titanate (2.5mmol), 2mL anhydrous 1, 2-dichloroethane were mixed, and heated at 85 ℃ under reflux for 15 hours. And (3) post-reaction treatment: quenching reaction with saturated ammonium chloride solution at 0 deg.C, vacuum filtering, collecting filtrate, extracting water phase with dichloromethane for 3 times, mixing organic phases, back-extracting with saturated saline solution, drying organic phase with anhydrous sodium sulfate, concentrating, and purifying by column chromatography to obtain a pair of diastereoisomer sulfinylimines (1: 1, each with 40% yield). The pair of diastereoisomeric sulfinamides obtained after purification is subsequently subjected to a respective hydrochloric acid hydrolysis, here for example a three-membered ring-up sulfinamide, which is dissolved in 5mL of methanol at 0 ℃ and stirred at room temperature for 6 hours with the addition of 2mol/L hydrochloric acid solution (2 mL). And (3) post-treatment: quenching the reaction with saturated ammonium carbonate solution at 0 deg.C, extracting the water phase with ethyl acetate for 3 times, mixing the organic phases, back-extracting with saturated saline, drying the organic phase with anhydrous sodium sulfate, concentrating, and purifying by column chromatography to obtain chiral ketone (colorless oily liquid, 95% yield) represented by formula (3).
1.3) the chiral ketone (1mmol) obtained in the previous step, a 50% strength by mass aqueous solution of hydroxylamine (5mmol of the substance of hydroxylamine) was dissolved in 2mL of ethanol and heated under reflux at 80 ℃ for 2 hours. And (3) post-treatment: to the reaction solution was added saturated brine, the aqueous phase was extracted 3 times with ethyl acetate, the organic phases were combined, the organic phase was dried over anhydrous sodium sulfate, and concentrated to give the oxime represented by formula (4) (pale yellow solid, 100% yield).
1.4) the oxime (1mmol) obtained in the previous step was dissolved in toluene, reduced iron powder (9mmol) was added, a mixture of acetic acid (5mmol) and acetic anhydride (5mmol) was added dropwise at 0 ℃ and stirred vigorously at room temperature for 3 hours. And (3) post-treatment: and (2) carrying out suction filtration, washing a filter cake with ethyl acetate, collecting filtrate, adjusting the pH value to 6-7 with a saturated sodium carbonate solution, extracting the water phase with ethyl acetate for 3 times, combining organic phases, carrying out back extraction with saturated saline solution, drying the organic phase with anhydrous sodium sulfate, concentrating, and carrying out column chromatography separation and purification to obtain the enamide (light yellow solid, 80% yield) shown in the formula (5).
1.5) in a 25mL dry Schlenk tube, adding the enamide (1mmol) obtained in the previous step, replacing nitrogen for 3 times, dropwise adding a mixture of N, N-dimethylformamide (5mL) and phosphorus oxychloride (8mmol) at 0 ℃, heating the system to 70 ℃ after dropwise adding, and reacting for 8 hours. And (3) post-treatment: diluting the reaction solution with 20mL of ethyl acetate at 0 ℃, slowly pouring the diluted solution into a proper amount of saturated sodium bicarbonate solution, adjusting the pH to 7-8, extracting the aqueous phase with ethyl acetate for 3 times, combining the organic phases, carrying out back extraction with saturated saline, drying the organic phase with anhydrous sodium sulfate, concentrating, and carrying out column chromatography separation and purification to obtain the chiral chloropyridine derivative (white solid, 86% yield) shown in the formula (6).
1.6) adding the chiral chloropyridine (1mmol) obtained in the previous step and 2mL of anhydrous dichloromethane into a 25mL dry branch mouth tube under anhydrous and oxygen-free conditions, dropwise adding a 1mol/L diisobutylaluminum hydride normal hexane solution (7 mL of diisobutylaluminum hydride) at 0 ℃ by using a constant pressure dropping funnel, and after the dropwise addition is finished, stirring at room temperature for 5 hours. And (3) post-treatment: slowly quenching the reaction with a saturated ammonium chloride solution at 0 ℃, adding 10mL of methanol, stirring for 30 minutes, extracting the aqueous phase with dichloromethane for 5-6 times, combining the organic phases, drying with anhydrous sodium sulfate, concentrating, and carrying out column chromatography separation and purification to obtain the chiral diol (white solid, 90% yield) shown in the formula (7).
1.7) in a dry Schlenk tube, the chiral diol (1mmol) obtained in the previous step, 2, 2-dimethoxypropane (2mmol), p-toluenesulfonic acid monohydrate (0.05mmol), stannous chloride (0.02mmol), an appropriate amount of 4A molecular sieve and 2mL of anhydrous 1, 2-dichloroethane are added and reacted for 7 hours at 90 ℃. And (3) post-treatment: the reaction solution was filtered with a buchner funnel, and the filter cake was washed with dichloromethane, and the filtrate was collected, concentrated, and subjected to column chromatography separation and purification to obtain a chiral chloropyridine derivative represented by formula (8) (white solid, 93% yield).
1.8) in a dry Schlenk tube, the chiral chloropyridine derivative (1mmol) obtained in the previous step, o-phenylenediamine (1.5mmol), palladium acetate (0.05mmol), 2,2 '-bis- (diphenylphosphino) -1,1' -binaphthyl (0.07mmol), and cesium carbonate (2mmol) were added, the reaction tube was purged with nitrogen three times, 1mL of anhydrous toluene was added under nitrogen flow, and the reaction was carried out at 90 ℃ for 12 hours. And (3) post-treatment: the reaction solution was filtered through a suction filter funnel, and the filter cake was washed with dichloromethane, and the filtrate was collected, concentrated, and purified by column chromatography to obtain a chiral pyridine derivative represented by formula (9) (white solid, 88% yield).
1.9) in a dry Schlenk tube, the chiral pyridine derivative (1mmol) obtained in the previous step and a silicon boron reagent PhMe are added2Si-B(NiPr2)2(1.2mmol), the reaction tube was purged with nitrogen three times, and 1mL of anhydrous toluene was added under nitrogen flow to conduct reaction at 135 ℃ for 24 hours. And (3) post-treatment: and (3) pumping the toluene under anhydrous and anaerobic conditions, and washing the obtained yellow solid with anhydrous N-hexane for 3 times (1 mL each time) to obtain a white solid, namely the chiral N, B ligand L shown in the formula (1).
Example 4
1.1) in a 10mL single-necked flask, bromocyclopentenone (1mmol), diethyl malonate (1.2mmol), tetrahexylammonium bromide (0.1mmol), potassium carbonate (6mmol), and 2mL of 1, 2-dichloroethane were added, and heated at 90 ℃ under reflux for 8 hours. And (3) post-treatment: the reaction solution was filtered through a buchner funnel, and the filter cake was washed with dichloromethane, collected, concentrated, and subjected to column chromatography to separate and purify the racemic ketone represented by formula (2) (colorless oily liquid, 86% yield).
1.2) racemic ketone (1mmol), (R) -t-butylsulfinamide (1mmol) represented by formula (2), tetraethyltitanate (2mmol), 2mL anhydrous 1, 2-dichloroethane were mixed and heated under reflux at 90 ℃ for 12 hours. And (3) post-reaction treatment: quenching reaction with saturated ammonium chloride solution at 0 deg.C, vacuum filtering, collecting filtrate, extracting water phase with dichloromethane for 3 times, mixing organic phases, back-extracting with saturated saline solution, drying organic phase with anhydrous sodium sulfate, concentrating, and purifying by column chromatography to obtain a pair of diastereoisomer sulfinylimines (1: 1, each with 40% yield). The pair of diastereoisomeric sulfinamides obtained after purification is subsequently subjected to a respective hydrochloric acid hydrolysis, here for example a three-membered ring-up sulfinamide, which is dissolved in 5mL of methanol at 0 ℃ and stirred at room temperature for 6 hours with the addition of 2mol/L hydrochloric acid solution (2 mL). And (3) post-treatment: quenching the reaction with saturated ammonium carbonate solution at 0 deg.C, extracting the water phase with ethyl acetate for 3 times, mixing the organic phases, back-extracting with saturated saline, drying the organic phase with anhydrous sodium sulfate, concentrating, and purifying by column chromatography to obtain chiral ketone (colorless oily liquid, 95% yield) represented by formula (3).
1.3) the chiral ketone (1mmol) obtained in the previous step, a 50% strength by mass aqueous solution of hydroxylamine (the amount of hydroxylamine substance is 3mmol) was dissolved in 2mL of ethanol and heated under reflux at 60 ℃ for 4 hours. And (3) post-treatment: to the reaction solution was added saturated brine, the aqueous phase was extracted 3 times with ethyl acetate, the organic phases were combined, the organic phase was dried over anhydrous sodium sulfate, and concentrated to give the oxime represented by formula (4) (pale yellow solid, 100% yield).
1.4) the oxime (1mmol) obtained in the previous step was dissolved in toluene, reduced iron powder (10mmol) was added, a mixture of acetic acid (4mmol) and acetic anhydride (5mmol) was added dropwise at 0 ℃ and stirred vigorously at room temperature for 4 hours. And (3) treatment: and (2) carrying out suction filtration, washing a filter cake with ethyl acetate, collecting filtrate, adjusting the pH value to 6-7 with a saturated sodium carbonate solution, extracting the water phase with ethyl acetate for 3 times, combining organic phases, carrying out back extraction with saturated saline solution, drying the organic phase with anhydrous sodium sulfate, concentrating, and carrying out column chromatography separation and purification to obtain the enamide (light yellow solid, 80% yield) shown in the formula (5).
1.5) in a 25mL dry Schlenk tube, adding the enamide (1mmol) obtained in the previous step, replacing nitrogen for 3 times, dropwise adding a mixture of N, N-dimethylformamide (3mL) and phosphorus oxychloride (7mmol) at 0 ℃, heating the system to 60 ℃ after dropwise adding, and reacting for 10 hours. And (3) post-treatment: diluting the reaction solution with 20mL of ethyl acetate at 0 ℃, slowly pouring the diluted solution into a proper amount of saturated sodium bicarbonate solution, adjusting the pH to 7-8, extracting the aqueous phase with ethyl acetate for 3 times, combining the organic phases, carrying out back extraction with saturated saline, drying the organic phase with anhydrous sodium sulfate, concentrating, and carrying out column chromatography separation and purification to obtain the chiral chloropyridine derivative (white solid, 86% yield) shown in the formula (6).
1.6) adding the chiral chloropyridine (1mmol) obtained in the previous step and 2mL of anhydrous dichloromethane into a 25mL dry branch mouth tube under anhydrous and oxygen-free conditions, dropwise adding a 1mol/L diisobutylaluminum hydride normal hexane solution (8 mL of diisobutylaluminum hydride) at 0 ℃ by using a constant pressure dropping funnel, and after the dropwise addition is finished, stirring at room temperature for 6 hours. And (3) post-treatment: slowly quenching the reaction with a saturated ammonium chloride solution at 0 ℃, adding 10mL of methanol, stirring for 30 minutes, extracting the aqueous phase with dichloromethane for 5-6 times, combining the organic phases, drying with anhydrous sodium sulfate, concentrating, and carrying out column chromatography separation and purification to obtain the chiral diol (white solid, 90% yield) shown in the formula (7).
1.7) in a dry Schlenk tube, the chiral diol (1mmol) obtained in the previous step, 2, 2-dimethoxypropane (1.5mmol), p-toluenesulfonic acid monohydrate (0.02mmol), stannous chloride (0.03mmol), an appropriate amount of 4A molecular sieve and 2mL of anhydrous 1, 2-dichloroethane are added and reacted for 6 hours at 100 ℃. And (3) post-treatment: the reaction solution was filtered with a buchner funnel, and the filter cake was washed with dichloromethane, and the filtrate was collected, concentrated, and subjected to column chromatography separation and purification to obtain a chiral chloropyridine derivative represented by formula (8) (white solid, 93% yield).
1.8) in a dry Schlenk tube, the chiral chloropyridine derivative (1mmol) obtained in the previous step, o-phenylenediamine (2mmol), palladium acetate (0.04mmol), 2,2 '-bis- (diphenylphosphino) -1,1' -binaphthyl (0.1mmol), and cesium carbonate (1.8mmol) were added, the reaction tube was purged with nitrogen three times, 1mL of anhydrous toluene was added under nitrogen flow, and the reaction was carried out at 90 ℃ for 16 hours. And (3) post-treatment: the reaction solution was filtered through a suction filter funnel, and the filter cake was washed with dichloromethane, and the filtrate was collected, concentrated, and purified by column chromatography to obtain a chiral pyridine derivative represented by formula (9) (white solid, 88% yield).
1.9) in a dry Schlenk tube, the chiral pyridine derivative (1mmol) obtained in the previous step and a silicon boron reagent PhMe are added2Si-B(NiPr2)2(1.3mmol), the reaction tube was purged with nitrogen three times, and 1mL of anhydrous toluene was added under a nitrogen stream to conduct a reaction at 125 ℃ for 36 hours. And (3) post-treatment: and (3) pumping the toluene under anhydrous and anaerobic conditions, and washing the obtained yellow solid with anhydrous N-hexane for 3 times (1 mL each time) to obtain a white solid, namely the chiral N, B ligand L shown in the formula (1).
The following examples further illustrate the use of the invention and do not therefore limit the scope of the invention described.
The application of pyridine derived chiral N, B ligand in iridium catalyzed asymmetric boronization reaction:
Figure BDA0002869186880000221
in an argon glove box, adding chiral N, B ligand L (3.9mg,0.008mmol), methoxy (cyclooctadiene) iridium dimer (2.7mg,0.004mmol) and bis (pinacolato) borate (76.2mg,0.3mmol, 1.5 times of the amount of a substrate triarylmethane substance) into a 10mL Schlenk tube, adding 1mL (0.2-0.4 mol/L) of N-hexane, stirring at room temperature for 30 minutes to 1 hour, then adding a substrate triarylmethane (49mg,0.2mmol), and continuing to react at 60-80 ℃ for 3-6 hours. The crude product obtained by the reaction was separated and purified by column chromatography to obtain a chiral boronated product represented by formula (11) (82% yield, 95% ee).
Application example 1: preparation of chiral arylboronic acid esters of formula (11).
Figure BDA0002869186880000222
The specific operation is as follows: in an argon glove box, chiral N, B ligand L (3.9mg,0.008mmol), methoxy (cyclooctadiene) iridium dimer (2.7mg,0.004mmol) and bis-pinacolato borate (76.2mg,0.3mmol) were added to a 10mL schlenk tube, 1mL N-hexane was added, stirring was carried out at room temperature for 30 minutes, then substrate S1(49mg,0.2mmol) was added, and the reaction was continued at 80 ℃ for 3 hours. The crude product obtained by the reaction was separated and purified by column chromatography to obtain a chiral boronated product represented by formula (11) (82% yield,95% ee). The nuclear magnetic data are as follows:1H NMR(400MHz,CDCl3)δ9.19(d,J=5.4Hz,1H),7.82–7.75(m,1H),7.72(td,J=7.8,1.7Hz,1H),7.48–7.33(m,6H),7.19(dd,J=14.4,7.5Hz,2H),7.08(td,J=7.6,1.3Hz,1H),6.78(d,J=7.7Hz,1H),6.02(s,1H),1.28(s,6H),1.20(s,6H)。13C NMR(100MHz,CDCl3)δ161.66,144.08,143.15,139.23,131.53,131.15,128.89,127.54,127.01,126.32,126.03,124.88,121.89,81.13,53.09,26.37,25.79。
application example 2: the substrate S2 is an asymmetric boronization/oxidation tandem reaction.
Figure BDA0002869186880000231
The specific operation is as follows: chiral N, B ligand L (3.9mg,0.008mmol), methoxy (cyclooctadiene) iridium dimer (2.7mg,0.004mmol) and bis-pinacolato borate (76.2mg,0.3mmol) were added to a 10mL schlenk tube in an argon glove box, 1mL N-hexane was added, stirring was carried out at room temperature for 30 minutes, then substrate S2(79.5mg,0.2mmol) was added and reaction was continued at 80 ℃ for 4 hours. After the reaction, the reaction solvent was concentrated off, 1mL of tetrahydrofuran was added again to dissolve the obtained crude boronated product, sodium perborate tetrahydrate (92.3mg,0.6mmol) was added and stirred at room temperature for 10 hours, and after the reaction was completed, the reaction solution was concentrated and the obtained crude product was separated and purified by column chromatography to obtain the chiral alcohol represented by formula (12) (92% yield, 96% ee). The nuclear magnetic data are as follows:1H NMR(400MHz,CDCl3)δ12.32(s,1H),8.59(d,J=4.4Hz,1H),7.85(td,J=7.7,1.6Hz,1H),7.61(d,J=7.4Hz,2H),7.57-7.52(m,3H),7.49–7.37(m,6H),7.36-7.27(m,5H),7.14(dd,J=7.8,1.7Hz,1H),7.08(d,J=8.1Hz,2H),5.39(s,1H);13C NMR(100MHz,CDCl3)δ162.53,156.87,148.32,142.65,140.94,140.77,140.45,139.57,138.75,132.45,128.80,128.22,127.39,127.25,127.16,127.13,126.83,124.77,122.77,118.68,118.41,58.64。
application example 3: the substrate S3 is an asymmetric boronization/oxidation tandem reaction.
Figure BDA0002869186880000232
The specific operation is as follows: chiral N, B ligand L (3.9mg,0.008mmol), methoxy (cyclooctadiene) iridium dimer (2.7mg,0.004mmol) and bis-pinacolato borate (76.2mg,0.3mmol) were added to a 10mL schlenk tube in an argon glove box, 1mL N-hexane was added, stirring was carried out at room temperature for 30 minutes, then substrate S3(69.1mg,0.2mmol) was added and reaction was continued at 80 ℃ for 4 hours. After the reaction was completed, the reaction solvent was concentrated off, 1mL of tetrahydrofuran was added again to dissolve the obtained crude boronated product, sodium perborate tetrahydrate (92.3mg,0.6mmol) was added and stirred at room temperature for 10 hours, and after the reaction was completed, the reaction solution was concentrated and the obtained crude product was separated and purified by column chromatography to obtain chiral alcohol represented by formula (13) (92% yield, 90% ee). The nuclear magnetic data are as follows:1H NMR(400MHz,DMSO)δ10.09(s,1H),8.55(dd,J=5.6,1.6Hz,1H),7.88–7.84(m,2H),7.80–7.74(m,2H),7.66(d,J=8.2Hz,1H),7.62–7.55(m,2H),7.47–7.45(m,2H),7.38–7.34(m,3H),7.28(dd,J=7.6,4.3Hz,2H),7.22-7.16(m,2H),6.18(s,1H);13C NMR(100MHz,DMSO)δ162.27,153.77,149.05,140.23,136.86,133.48,132.97,132.48,131.75,129.15,128.02,127.64,127.51,127.48,127.43,127.23,126.09,125.82,125.66,125.45,123.81,122.80,121.72,108.99,52.78。
application example 4: the substrate S4 is an asymmetric boronization/oxidation tandem reaction.
Figure BDA0002869186880000241
The specific operation is as follows: chiral N, B ligand L (3.9mg,0.008mmol), methoxy (cyclooctadiene) iridium dimer (2.7mg,0.004mmol) and bis-pinacolato borate (76.2mg,0.3mmol) were added to a 10mL schlenk tube in an argon glove box, 1mL N-hexane was added, stirring was carried out at room temperature for 30 minutes, then substrate S4(62.8mg,0.2mmol) was added and reaction was continued at 80 ℃ for 3 hours. After the reaction is finished, the reaction solvent is concentrated, 1mL of tetrahydrofuran is added again to dissolve the obtained crude boronized product, sodium perborate tetrahydrate (92.3mg,0.6mmol) is added, the mixture is stirred for 10 hours at room temperature, after the reaction is finished,the reaction solution was concentrated, and the obtained crude product was separated and purified by column chromatography to give a chiral alcohol represented by formula (14) (87% yield, 94% ee). The nuclear magnetic data are as follows:1H NMR(400MHz,CDCl3)δ12.16(s,1H),8.56(d,J=4.6Hz,1H),7.85(td,J=7.7,1.4Hz,1H),7.48(d,J=7.7Hz,1H),7.35(dd,J=7.3,5.2Hz,1H),7.23(d,J=2.4Hz,1H),7.20–7.11(m,3H),6.91-6.84(m,3H),5.20(s,1H);13C NMR(100MHz,CDCl3)δ161.28,155.22,148.38,142.72,138.97,134.37,131.24,129.62,129.35,128.89,127.97,127.09,125.99,124.77,124.27,123.16,121.05,57.84。
application example 5: the substrate S5 is an asymmetric boronization/oxidation tandem reaction.
Figure BDA0002869186880000251
The specific operation is as follows: chiral N, B ligand L (3.9mg,0.008mmol), methoxy (cyclooctadiene) iridium dimer (2.7mg,0.004mmol) and bis-pinacolato borate (76.2mg,0.3mmol) were added to a 10mL schlenk tube in an argon glove box, 1mL N-hexane was added, stirring was carried out at room temperature for 30 minutes, then substrate S5(76.3mg,0.2mmol) was added and reaction was continued at 80 ℃ for 3 hours. After the reaction was completed, the reaction solvent was concentrated off, 1mL of tetrahydrofuran was added again to dissolve the obtained crude boronated product, sodium perborate tetrahydrate (92.3mg,0.6mmol) was added and stirred at room temperature for 10 hours, and after the reaction was completed, the reaction solution was concentrated and the obtained crude product was separated and purified by column chromatography to obtain chiral alcohol represented by formula (14) (80% yield, 91% ee). The nuclear magnetic data are as follows:1H NMR(400MHz,CDCl3)δ12.76(s,1H),8.58(d,J=4.6Hz,1H),7.90(td,J=7.7,1.5Hz,1H),7.59–7.51(m,2H),7.51–7.43(m,2H),7.42–7.31(m,2H),7.20–7.08(m,2H),7.03(dd,J=8.3,2.5Hz,1H),5.38(s,1H);13C NMR(100MHz,CDCl3)δ161.07,159.73,148.37,141.48,139.34,131.09,130.81(q,JCF=32.0Hz),129.02,127.34,127.14(q,JCF=3.7Hz),124.64(q,JCF=269.4Hz),124.12(q,JCF=270.7Hz),124.91,124.48(q,JCF=3.8Hz),123.94(q,JCF=3.7Hz),123.45,122.05(q,JCF=32.4Hz),120.20,58.41。
the invention designs and synthesizes the chiral N and B ligands with rigid condensed ring structural frameworks and adjustable structural height, and the chiral ligands show excellent reaction activity and enantioselectivity in the iridium-catalyzed asymmetric boronization reaction. The invention provides a new framework chiral ligand for the development of asymmetric catalysis, and provides a new method for preparing the chiral aryl boron compound. The obtained chiral aryl boron product can be used for synthesizing functional material molecules and has potential industrial application value.

Claims (10)

1. The chiral pyridine derived N, B ligand is characterized by having a structural general formula shown as formula (1):
Figure FDA0003293572900000011
r is methyl, ethyl, isopropyl, benzyl, 3, 5-dimethylbenzyl, 3, 5-diisopropylbenzyl, 3, 5-di-tert-butylbenzyl, 3, 5-diphenylbenzyl, phenyl, 3, 5-dimethylphenyl, 3, 5-dimethoxyphenyl, 3, 5-diisopropylphenyl, 3, 5-di-tert-butylphenyl or 3, 5-diphenylphenyl.
2. The preparation method of the N, B ligand derived from chiral pyridine is characterized in that the chiral pyridine derivative shown as the formula (9) and PhMe are mixed2Si-B(NiPr2)2Reacting in toluene at 125-135 ℃ to obtain chiral pyridine-derived N, B ligand shown in formula (1);
Figure FDA0003293572900000012
wherein R is methyl, ethyl, isopropyl, benzyl, 3, 5-dimethylbenzyl, 3, 5-diisopropylbenzyl, 3, 5-di-tert-butylbenzyl, 3, 5-diphenylbenzyl, phenyl, 3, 5-dimethylphenyl, 3, 5-dimethoxyphenyl, 3, 5-diisopropylphenyl, 3, 5-di-tert-butylphenyl or 3, 5-diphenylphenyl.
3. The method for preparing the chiral pyridine-derived N, B ligand according to claim 2, which comprises the following steps: under nitrogen atmosphere, 1mmol of chiral pyridine derivative shown as formula (9) and 1.1-1.3 mmol of PhMe2Si-B(NiPr2)2And mixing the chiral pyridine and anhydrous toluene, and then reacting for 24-36 h at 125-135 ℃ to obtain the chiral pyridine derived N, B ligand.
4. The method for preparing a chiral pyridine-derived N, B ligand according to claim 2, wherein the chiral pyridine derivative represented by formula (9) is prepared by the following process:
mixing chiral diol, ketal, p-toluenesulfonic acid, stannous chloride and dichloroethane shown in formula (7), and reacting at 80-100 ℃ to obtain chiral chloropyridine derivative shown in formula (8);
Figure FDA0003293572900000021
the ketal formula is as follows:
Figure FDA0003293572900000022
wherein R is methyl, ethyl, isopropyl, benzyl, 3, 5-dimethylbenzyl, 3, 5-diisopropylbenzyl, 3, 5-di-tert-butylbenzyl, 3, 5-diphenylbenzyl, phenyl, 3, 5-dimethylphenyl, 3, 5-dimethoxyphenyl, 3, 5-diisopropylphenyl, 3, 5-di-tert-butylphenyl or 3, 5-diphenylphenyl;
mixing a chiral chloropyridine derivative shown in a formula (8) and phenylenediamine in palladium acetate, 2 '-bis- (diphenylphosphino) -1,1' -binaphthyl and toluene, and then carrying out C-N bond coupling reaction to obtain a chiral pyridine derivative shown in a formula (9);
Figure FDA0003293572900000023
5. the process for the preparation of chiral pyridine derived N, B ligands according to claim 4,
mixing chiral diol, ketal, p-toluenesulfonic acid, stannous chloride, a 4A molecular sieve and anhydrous dichloroethane, and stirring at 80-100 ℃ for 4-8 h to obtain a chiral chloropyridine derivative shown in a formula (8); wherein the ratio of the amounts of the chiral diol, the ketal, the p-toluenesulfonic acid and the stannous chloride is 1: (1.5-2): (0.02-0.05): (0.02-0.05);
mixing the chiral chloropyridine derivative shown in the formula (8), o-phenylenediamine, palladium acetate, 2,2 '-bis- (diphenylphosphino) -1,1' -binaphthyl, cesium carbonate and anhydrous toluene under a nitrogen atmosphere, and stirring at 90-100 ℃ for 10-16 h to obtain the chiral pyridine derivative shown in the formula (9); wherein the ratio of the amounts of the chiral chloropyridine derivative, o-phenylenediamine, palladium acetate, 2 '-bis- (diphenylphosphino) -1,1' -binaphthyl and cesium carbonate is 1: (1.2-2): (0.02-0.05): (0.04-0.1): (1.5-2).
6. The method of claim 4, wherein the chiral diol is prepared by the following steps:
(1) performing cyclopropanation reaction on bromo-cyclopentenone and malonic diester to generate ketone shown in a formula (2);
Figure FDA0003293572900000031
wherein R is1Is methyl, ethyl, isopropyl, tert-butyl or benzyl;
(2) reacting ketone shown in a formula (2) with (R) -tert-butyl sulfinamide and tetraethyl titanate to obtain sulfinyl imine, and hydrolyzing to obtain chiral ketone shown in a formula (3) or a formula (3');
Figure FDA0003293572900000032
(3) placing chiral ketone shown in a formula (3) or a formula (3') and hydroxylamine into ethanol for reaction to obtain oxime shown in a formula (4);
Figure FDA0003293572900000033
(4) adding oxime shown in a formula (4) into toluene, adding iron powder, acetic anhydride and acetic acid, and reacting to obtain enamide shown in a formula (5);
Figure FDA0003293572900000034
(5) dissolving the enamine shown in the formula (5) in N, N-dimethylformamide, then dropwise adding phosphorus oxychloride, and reacting to obtain the chiral chloropyridine derivative shown in the formula (6);
Figure FDA0003293572900000041
(6) the chiral chloropyridine derivative shown in the formula (6) is dissolved in dichloromethane, and an ester group is reduced to a hydroxyl group by diisobutylaluminum hydride to obtain a chiral diol.
7. The process for the preparation of chiral pyridine derived N, B ligands according to claim 6,
the specific process of the step (1) is as follows: mixing bromo-cyclopentenone, diethyl malonate, tetrahexylammonium bromide, potassium carbonate and 1, 2-dichloroethane, and stirring at 80-90 ℃ for 8-12 hours to obtain racemic ketone shown in formula (2); wherein the mass ratio of the brominated cyclopentenone, diethyl malonate, tetrahexylammonium bromide and potassium carbonate is 1: (1.0-1.5): (0.1-0.2): (4-6);
the specific process of the step (2) is as follows: mixing racemic ketone (R) -tert-butyl sulfenamide shown in formula (2), tetraethoxytitanate and anhydrous 1, 2-dichloroethane, and stirring at 80-90 ℃ for 12-18 h to obtain a pair of enantiomeric ketone shown in formula (3) and formula (3'); wherein the ratio of the amounts of racemic ketone, (R) -tert-butylsulfinamide, tetraethyl titanate is 1: (1.0-1.5): (2-3);
the specific process of the step (3) is as follows: dissolving chiral ketone and hydroxylamine aqueous solution shown in formula (3) or formula (3') in ethanol, and stirring for 2-4 h at 60-80 ℃; obtaining oxime represented by a formula (4); wherein the ratio of the amount of substance of chiral ketone to hydroxylamine is 1: (3-5).
8. The process for the preparation of chiral pyridine derived N, B ligands according to claim 6,
the specific process of the step (4) is as follows: dissolving oxime shown in a formula (4) in toluene, then adding reduced iron powder, dropwise adding a mixture of acetic acid and acetic anhydride at 0 ℃, and stirring for 2-4 h to obtain enamide shown in a formula (5); wherein the mass ratio of the oxime, the reduced iron powder, the acetic acid and the acetic anhydride is 1: (8-10): (3-5): (3-5);
the specific process of the step (5) is as follows: dissolving enamine shown in a formula (5) in anhydrous N, N-dimethylformamide, dropwise adding phosphorus oxychloride at 0 ℃, heating to 60-80 ℃ after dropwise adding, and reacting for 6-10 h to obtain chiral chloropyridine derivatives shown in a formula (6); wherein the mass ratio of the enamine to the phosphorus oxychloride is 1: (7-10);
the specific process of the step (6) is as follows: dissolving the chiral chloropyridine derivative shown in the formula (6) in anhydrous dichloromethane, dropwise adding n-hexane solution of diisobutyl aluminum hydride at 0 ℃, and stirring at room temperature for 4-6 hours after dropwise adding to obtain chiral diol shown in the formula (7); wherein the dosage ratio of the chiral chloropyridine derivative to the diisobutylaluminum hydride is 1 mmol: 6-8 mL.
9. Use of a chiral pyridine-derived N, B ligand according to claim 1 in iridium-catalysed asymmetric boriding reactions.
10. The application of the compound as claimed in claim 9, wherein the chiral N, B ligand, methoxy (cyclooctadiene) iridium dimer and bis pinacol borate are pre-stirred in N-hexane for 5-30 min, diarylpyridine is added, stirring is carried out at 60-80 ℃ for 2-8 h, and purification is carried out to obtain the chiral arylboron compound; wherein the ratio of the chiral N, B ligand, methoxy (cyclooctadiene) iridium dimer, bis (pinacolato) borate to diarylpyridine is (0.04-0.1): (0.02-0.05): (1.2-2): 1.
CN202011602455.2A 2020-12-29 2020-12-29 Chiral pyridine derived N, B ligand, preparation method and application in iridium-catalyzed asymmetric boronation reaction Active CN112724168B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011602455.2A CN112724168B (en) 2020-12-29 2020-12-29 Chiral pyridine derived N, B ligand, preparation method and application in iridium-catalyzed asymmetric boronation reaction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011602455.2A CN112724168B (en) 2020-12-29 2020-12-29 Chiral pyridine derived N, B ligand, preparation method and application in iridium-catalyzed asymmetric boronation reaction

Publications (2)

Publication Number Publication Date
CN112724168A CN112724168A (en) 2021-04-30
CN112724168B true CN112724168B (en) 2021-12-28

Family

ID=75610600

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011602455.2A Active CN112724168B (en) 2020-12-29 2020-12-29 Chiral pyridine derived N, B ligand, preparation method and application in iridium-catalyzed asymmetric boronation reaction

Country Status (1)

Country Link
CN (1) CN112724168B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114014869B (en) * 2021-11-29 2023-03-24 西安交通大学 Chiral 2,2' -bipyridine ligand and preparation method and application thereof
CN113980044B (en) * 2021-12-03 2023-02-03 西安交通大学 Preparation method of Ir-O-P type catalyst diboronic acid/ester compound

Also Published As

Publication number Publication date
CN112724168A (en) 2021-04-30

Similar Documents

Publication Publication Date Title
Fava et al. Photoredox-catalyzed ketyl–olefin coupling for the synthesis of substituted chromanols
CN112724168B (en) Chiral pyridine derived N, B ligand, preparation method and application in iridium-catalyzed asymmetric boronation reaction
Okamoto et al. Allylic substitution reactions with Grignard reagents catalyzed by imidazolium and 4, 5-dihydroimidazolium carbene–CuCl complexes
CN111423381B (en) Preparation method of 2-trifluoromethyl substituted imidazole compound
Nelson et al. Chemo-, regio-, and stereoselective copper (II)-catalyzed boron addition to acetylenic esters and amides in aqueous media
CN105732387B (en) The method of novel C -2` phase transfer catalyst photooxidation beta-dicarbonyl compound asymmetry 'alpha '-hydroxylation
Nie et al. Chiral bifunctional thiourea-catalyzed enantioselective aldol reaction of trifluoroacetaldehyde hemiacetal with aromatic ketones
WO2012102247A1 (en) Ruthenium complex-containing catalyst for hydrogen transfer reaction and method for producing hydrogen transfer reaction product
CN101219399B (en) Preparation method and application of N-heterocyclic carbine metal palladium catalyst
Ye et al. Enantioselective assembly of ferrocenes with axial and planar chiralities via palladium/chiral norbornene cooperative catalysis
CN111233852B (en) NON type chiral bisoxazoline ligand and synthetic method and application thereof
CN104744394B (en) A kind of method of asymmetric synthesis containing trifluoromethyl chirality quaternary carbon compound
CN107793357A (en) A kind of preparation method of 6 substitution phenanthridines class compound
CN105646382A (en) Preparation method of 1,3,5-trisubstituted 1,2,4-triazole compound
CN102977017A (en) Method for catalytically preparing 6(5H)-phenanthridine ketone by copper component
CN111217809B (en) Chiral nitrogen-containing diene ligand and preparation method and application thereof
CN110078662B (en) Preparation method of 3-acyl methyl-2, 2' -bipyridine-6-formamide derivative
Niu et al. Enantioselective addition of alkynylzinc to arylaldehydes catalyzed by azetidino amino alcohols bearing an additional stereogenic center
CN112430228B (en) Chiral 2, 3-dihydrobenzo [ b ] thiophene 1, 1-dioxide, derivative and preparation method
CN102633738A (en) Chiral zinc complex
CN114560892A (en) Chiral tridentate nitrogen phosphine ligand synthesized based on ferrocene skeleton and application thereof
CN111718363B (en) Preparation method of borate compound
CN103242223B (en) Preparation method of 2-pyridineoxydiaryl ketone derivative
CN102627571B (en) Preparation and synthesis method for chiral ammonium salt
Fok et al. Intramolecular hydroamination of trisubstituted aminoallenes catalyzed by titanium complexes of diaryl substituted tridentate imine-diols

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant